Record Breaking M&A in MedTech

This article is brought to you by Equifund, LLC.

Share on facebook
Share on twitter
Share on linkedin

2020 was a record-breaking year in almost all categories of fundraising and exits…

Which, in turn, appears to have set the stage for 2021 to be a record-smashing year across what seems like all categories.

In exits… venture backed companies have been dominating headlines with record numbers of IPOs.

In 2020, we saw big-names – like DoorDash and Airbnb – go public. In 2021, we’ve seen companies like Affirm, Robinhood, Toast, LegalZoom, Roblox, Coinbase, Warby Parker, and SoFi make the jump.

And this smattering of exits means there’s plenty of investment capital looking for somewhere to go. That’s why it’s no surprise to see…

In fundraising… venture capitalists are closing in on $100 billion in fundraising (vs the $85bn record set in 2020) and have an estimated $22 billion of “dry powder” ready to deploy.

In funding… We are on track to hit $454 billion invested through the first three quarters of 2021. In 2020, it was a mere $332 billion invested globally across all funding stages.

In unicorns… we’ve never had so many private companies cross the $1bn threshold.

So far this year, 413 new companies have joined the Crunchbase Unicord Board; the list has swelled to over 1,000 companies, collectively valued north of $3.4 trillion.

With many growth companies raising funding at an unprecedented pace, the IPO market shows signs of remaining strong through the end of the year and into 2022 (however, there’s no guarantee it will).

But there’s one sector pretty much no one is talking about that I want to bring your attention to today.

The Explosion of MedTech M&A

MedTech dealmaking started with a bang in 2021.

With elective surgeries dramatically declining in 2020, device makers were hesitant to spend money.

However, as elective surgeries started to rebound in late 2020, companies flush with cash decided to move fast in 2021.

With at least 10 deals announced in January alone, the MedTech industry notched 33 deals worth $19bn in the first half of 2021 (vs 25 deals worth $34bn in all of 2020).

Scott Tuhy, lead medical device analyst for Moody’s Investor Service, said the diversity of deals made during the first six months of the year has been a noticeable trend, with M&A happening across multiple sectors.

“We’ve seen transactions in diagnostics, cardiology, dental,” Tuhy said. “There were certainly times in the past where deals were often focused on one sector, but what really just stood out is that we’ve seen such a broad array of transactions.”

Here’s a look at some of this year’s notable (and diverse) MedTech M&As.

  • On Jan 12th, Steris (NYSE:STE) announced its $4.6bn takeover of Cantel Medical (NYSE:CMD), a global provider of infection prevention products and services primarily to endoscopy and dental customers.
  • On January 21st, Boston Scientific (NYSE:BSX) announced it’s $925 million acquisition of Preventice Solutions (with $300m in potential commercial milestone payments). The Preventice product portfolio includes the BodyGuardian® family of remote, wearable cardiac monitors for adult and pediatric patients.
  • On February 24th, NuVasive (NASDAQ: NUVA) announced their $150m acquisition of Simplify Medical to expand it’s cervical spine technology portfolio.
  • On March 3rd, Boston Scientific (NYSE:BSX) announced it’s $1.07bn acquisition of Lumenis. The Lumenis surgical business includes premier laser systems, fibers and accessories used for urology and otolaryngology procedures.
  • On April 8th, Hologic (NASDAQ:HOLX) announced their $795 million acquisition of Mobidiag, a privately held, commercial-stage Finnish-French developer of innovative molecular diagnostic tests and instrumentation.
  • On April 15th, Thermo Fisher Scientific (NYSE:TMO) announced their $17.4bn acquisition of PPD, Inc (NASDAQ: PPD), a leading contract research organization (aka “CROs”).
  • On August 6th, Medtronic (NYSE:MDT) announced their $1.1bn acquisition of Intersect ENT (NASDAQ: XENT), a Menlo Park, Calif.-based medtech focused on treatments for chronic rhinosinusitis.
  • On August 9th, Philip Morris International (NYSE:PM) announced their $1.5bn acquisition of OtiTopic, a developer of an inhaled treatment for acute myocardial infarction; the acquisition is part of PMI’s strategic plan to leverage its expertise, scientific know-how, and capabilities in inhalation to grow a pipeline of inhaled therapeutics and respiratory drug delivery (and move “Beyond Nicotine”).
  • On Sept 2, Baxter (NYSE:BAX) announced a $10.5bn acquisition of Hillrom (NYSE:HRC), a medical technology company focused on enabling “earlier diagnosis and treatment, optimize surgical efficiency and accelerate patient recovery while simplifying clinical communication and shifting care closer to home”
  • On Sept 23, General Electric (NYSE:GE) announced it’s $1.45bn acquisition of BK Medical, an innovator in global intraoperative imaging and surgical navigation, used to guide clinicians during minimally invasive and robotic surgeries and to visualize deep tissue during procedures in neuro and abdominal surgery, and in ultrasound urology.
  • On Oct 6th, Boston Scientific (NYSE:BSX) announced it’s $1.75bn acquisition of Baylis Medical Company, who specializes in devices that facilitate access to the left side of the heart, which can be used for procedures like atrial fibrillation ablation, left atrial appendage closure and mitral valve interventions. The deal marks Boston Scientifics third ~$1bn acquisition of 2021.

To make the 2021 MedTech M&A landscape even more interesting, the largest MedTech’s have billions of dollars in cash stockpiled.


It’s anyone’s guess as to how Q4 will shape up. But for investors interested in MedTech, it seems there’s never been a better market than right now for M&A.


Jake Hoffberg

Jake Hoffberg – Publisher

Like this article? Share it with a friend:

Share on facebook
Share on twitter
Share on linkedin

This article is not an Equifund Crowd Funding Portal Inc communication. It is brought to you by Equifund, LLC.

More Articles:

The Era of Net-Zero Mining

28 mining and metals companies commit to a goal of net-zero direct and indirect carbon emissions by 2050 or sooner

Don't make another private market investment without reading this...

The 5 Mistakes

investors make that crush returns

Download this free report now:

Just enter your name & email to access this report for free.

By submitting your email address you will receive access to this report and a free subscription to Equifund’s private investment newsletter. You can unsubscribe at any time and read more about our privacy policy here.

More Articles:


Kleiner Device Labs

Investment Highlights:

  • 1

    Proprietary devices that could revolutionize spinal surgery and greatly improve success rates, reduce pain, and lower costs.

  • 2

    Over 20 patents have been issued to protect the company's technologies.

  • 3

    Just received FDA clearance for their next-generation KG2 spinal fusion technology.

Pre-Investment Agreement

The next 8 slides will allow us to process your investment. Note that these next steps are a legal requirement – Thank you for your patience and financial support of this investment opportunity. Jordan Gillissie – CEO

Before we execute the investment, it’s important for us to make sure you’re comfortable and knowledgeable in early stage investing. We want to make sure that you:

    • Received and have reviewed the education materials sent to you.
    • UNDERSTAND; that there are restrictions on your ability to cancel your investment commitment and obtain a return of your investment.
    • KNOW; It may be difficult to resell securities acquired under Regulation Crowdfunding.
    • AGREE; investing in securities offered and sold in reliance on section 4(a)(6) of the Securities Act involves risk. Investors should not invest any funds unless he or she can afford to lose the entire amount of his or her investment. Your investment may not work out, and you must be in a financial condition to bear the loss.
  • Hidden
  • Hidden
  • Hidden
  • Hidden

We are currently upgrading our system. If you click submit and the process does not continue in a few seconds, please refresh this page manually, and click Invest Now again and you should be moved on to the next step.

Complete Your Registration

By verifying your account you agree with our terms of use, privacy policy and pre-dispute arbitration agreement. Please complete the registration process by clicking the link below:

Verify Your Email

Please wait a few minutes while we create your account. An email will be sent to you shortly to confirm your admittance. Should the email be delivered to your spam or promotions folder, we recommend you move it to your inbox and mark Equifund as a safe sender.

If you have not received the email in 5 minutes, please click here to have it resent.

Questions? Our customer service team is always here to help – (800) 879-7606

Thank you for your investment in Home Bistro! To view the status of your investment, click the button below to navigate to your Dashboard.

Enter your email address to get instant access to the video: